| Dr Bryan D Stone, MD | |
|
500 Merrimack St, Riverwalk, Lawrence, MA 01843-1756 | |
| (978) 557-8900 | |
| (978) 557-8944 |
| Full Name | Dr Bryan D Stone |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 38 Years |
| Location | 500 Merrimack St, Lawrence, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720095144 | NPI | - | NPPES |
| 060030 | Other | MA | TUFTS |
| AA100709 | Other | MA | HARVARD PILGRIM HEALTH CARE |
| 0043949 | Other | MA | NEIGHBORHOOD HEALTH PLAN |
| E82846 | Other | NH | ANTHEM BS |
| 1720095144 | Other | MA | FALLON COMMUNITY HEALTH PLAN |
| J1097301 | Other | MA | MEDICARE PTAN |
| 1720095144 | Other | MA | AETNA HMO |
| 30204073 | Medicaid | NH | |
| 4259414 | Other | MA | AETNA NON HMO |
| 980197-02 | Other | MA | NETWORK HEALTH PLAN |
| P00693203 | Other | MA | RAILROAD MEDICARE |
| 0153496 | Other | MA | CIGNA |
| 110003929A | Other | MA | MASSHEALTH |
| J10973 | Other | MA | BCBS |
| J10973 | Other | MA | HMO BLUE |
| 02-02017 | Other | MA | EVERCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 8600 (New Hampshire) | Secondary |
| 207KA0200X | Allergy & Immunology - Allergy | 60030 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Shore Medical Center - | Salem, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mass General Brigham Community Physicians Inc | 1759273436 | 297 |
News Archive
eHealth Global Technologies, Inc. (eHGT) announces eHealth Access Indexing™. This latest service further simplifies the way physicians obtain clinical records using eHGT's already successful eHealth AccessTM Record Retrieval Service. Having patients' records fully indexed and organized, by date and type of report, and delivered in digital format, saves valuable staff time. This provides physicians the ability to quickly and easily access critical clinical data in minutes instead of hours.
Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics' CRISPR/Cas9 patent portfolio.
Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online in the journal Nature Medicine.
› Verified 5 days ago
| Entity Name | Mass General Brigham Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891112637 PECOS PAC ID: 1759273436 Enrollment ID: O20150723007726 |
News Archive
eHealth Global Technologies, Inc. (eHGT) announces eHealth Access Indexing™. This latest service further simplifies the way physicians obtain clinical records using eHGT's already successful eHealth AccessTM Record Retrieval Service. Having patients' records fully indexed and organized, by date and type of report, and delivered in digital format, saves valuable staff time. This provides physicians the ability to quickly and easily access critical clinical data in minutes instead of hours.
Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics' CRISPR/Cas9 patent portfolio.
Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online in the journal Nature Medicine.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bryan D Stone, MD 500 Merrimack St, Riverwalk, Lawrence, MA 01843-1756 Ph: (978) 557-8900 | Dr Bryan D Stone, MD 500 Merrimack St, Riverwalk, Lawrence, MA 01843-1756 Ph: (978) 557-8900 |
News Archive
eHealth Global Technologies, Inc. (eHGT) announces eHealth Access Indexing™. This latest service further simplifies the way physicians obtain clinical records using eHGT's already successful eHealth AccessTM Record Retrieval Service. Having patients' records fully indexed and organized, by date and type of report, and delivered in digital format, saves valuable staff time. This provides physicians the ability to quickly and easily access critical clinical data in minutes instead of hours.
Today, Abbott presents results from a pooled analysis of two pivotal HUMIRA® (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta.
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics' CRISPR/Cas9 patent portfolio.
Adding an artificial tumor-specific receptor to immune system cells called T-lymphocytes that target a particular virus extended and improved the cells' ability to fight a form of childhood cancer called neuroblastoma, said researchers form Baylor College of Medicine and Texas Children's Hospital in a report that appears online in the journal Nature Medicine.
› Verified 5 days ago
Bruce E. Birkby, M.D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 500 Merrimack St, Riverwalk, Lawrence, MA 01843 Phone: 978-557-8900 Fax: 978-557-8944 |